Leqembi® revenue totaled JPY 10 billion in the third quarter 2024

STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024, in conjunction with their partner Biogen's quarterly report. In total, sales of JPY 10 billion were recorded in the quarter, an increase of approximately 60% compared to the previous quarter (Q2 2024: JPY 6.3 billion), resulting in a royalty to BioArctic amounting to approximately SEK 70 million.

Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region and pending European approval Eisai and BioArctic are preparing for a joint commercialization in the region.

BioArctic's report for the third quarter 2024 will be published on November 14 at 08.00 a.m. CET.

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on October 30, 2024, at 11.45 a.m. CET.

For further information, please contact: Oskar Bosson, VP Communications and IRE-mail:  +46 70 410 71 80

About lecanemab (Leqembi®)

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of ...